jama glp-1 discontinuation and re-initiation trends Glucagon-like peptide-1 (GLP-1) receptor agonists

Like other incretin-based medications, the most common side effects were gastrointestinal: Common Side Effects Nausea: Reported in approximately 25-45% of participants depending on dose (most common during titration) Diarrhea: Approximately 20-35% of participants Vomiting: Approximately 10-20% of participants Constipation: Approximately 10-15% of participants Decreased appetite: Common and expected given the mechanism of action Less Common but Notable Effects Increased heart rate: Small elevations in resting heart rate were observed, consistent with other GLP-1 class medications Injection site reactions: Mild redness or itching at injection sites Fatigue: Reported by some participants, particularly during dose escalation Most adverse events were mild to moderate and occurred primarily during the dose escalation phase

n = 7), immunomodulatory (IM

Reproductive problems may include: Infertility

In research models the two molecules act on parallel pathways of the growth hormone axis

Dry mouth is a known side effect of GLP-1 activation, not a marker of therapeutic efficacy